Article Text

PDF
FRI0275 Long-Term Survival and Baseline Prognostic Factors in a Wide Series of Patients with AAV from Spain. Usefulness of Prognostic Scores (Revas Study)
  1. R. Solans-Laqué1,
  2. M. Rodriguez-Carballeira2,
  3. G. Fraile3,
  4. M.J. Castillo4,
  5. J. Rios5,
  6. L. Saez6,
  7. X. Solanich7,
  8. L. Caminal8,
  9. J. Oristrell9,
  10. F. Pasquau10,
  11. E. Fonseca11,
  12. J. Calleja12,
  13. M. Zamora13,
  14. P. Fanlo14,
  15. M. Abdilla15,
  16. I. Garcia16,
  17. B. Sopeña17,
  18. M. Lopez-Dupla18,
  19. A. Pérez19,
  20. B. Frutos20
  21. on behalf of GEAS-SEMI
  1. 1Internal Medicine, H Vall Hebron
  2. 2I Medicine, H Mutua Terrassa, Barcelona
  3. 3I Medicine, H Ramon y Cajal, Madrid
  4. 4Internal Medicine, H Virgen del Rocio, Sevilla
  5. 5I Medicine, HU La Paz, Madrid
  6. 6I Medicine, H Miguel Servet, Zaragoza
  7. 7I Medicine, HU Bellvitge, Barcelona
  8. 8I Medicine, H Central Asturias, Oviedo
  9. 9I Medicine, H Parc Tauli, Sabadell, Barcelona
  10. 10I Medicine, H Marina Baixa, Alicante
  11. 11I Medicine, H Cabueñes, Asturias
  12. 12I Medicine, H San Cecilio
  13. 13I Medicine, H Virgen Nieves, Granada
  14. 14I Medicine, Clinica Navarra, Navarra
  15. 15I Medicine, H La Ribera, Valencia
  16. 16I Medicine, H Infanta Leonor, Madrid
  17. 17I Medicine, C H U Vigo, Vigo
  18. 18I Medicine, H Joan XXIII, Tarragona
  19. 19I Medicine, C H U, Orense
  20. 20I Medicine, H Fuen Labrada, Madrid, Spain

Abstract

Background AAV are still related to a high morbidity and mortality in spite of therapeutic advances.To identify factors present at diagnosis that are associated with a worse prognosis, it is essential to tailoring the treatment

Objectives To describe the long-term survival rate and possible prognostic factors at presentation in a large cohort of patients with AAV from Spain, and compare BVAS a FFS prognostic scores

Methods Multicenter retrospective-longitudinal study that included patients diagnosed with AAV between Jan1995 and Dec 2013 in 20 Hospitals from Spain (REVAS Study). Statistical analysis was done using SPSS vs19.

Results Four hundred and fifty patients (50.4% men) were included: 184 GPA,167 MPA and 99 EGPA. ANCA were positive in 86.4% of cases:36.2% C-ANCA, 50.2% P-ANCA. Mean age at diagnosis was 55.6±17.4 y. Mean time to diagnosis was 4 weeks (0-240). The most frequent symptoms at diagnosis were fever (53%),constitutional symptoms (51%), arthralgia (53%), hypertension (29%), purpura (20%) and hemoptisis (19%). Renal failure was present in 47% of cases, lung involvement in 45.3%, pulmonary-renal syndrome in 16%,and cardiac involvement in 11%. Sensory peripheral neuropathy was detected in 16% of cases,mononeuritis multiplex in 28% and CVA in 4.5%. ENT was observed in 35% and eye involvement in 20%. All patients received oral glucocorticoids. Cyclophosphamide was given to 286 patients (45.3%IV and 38% oral). Dialysis was required in 19% of cases and plasma exchange in 7%. During the follow-up 40% of patients suffered bacterial infections, 10% sepsis 14.6% opportunistic infections and 6% neoplasms. One hundred and twenty-nine (28.7%) died: 74 (44.3%) with MPA,41 (22.3%) with WG and 14 (14%) with CSS. Mean survival was 82.5 months (0-307). Mortality was significantly higher in MPA (p=0.00). Poor prognosis factors at diagnosis were renal failure (HR 1.6),cardiac failure (HR 3.3),bacterial infections (HR 1.8)and age at diagnosis >65y (HR 4.1).BVAS and FFS were significantly associated with outcome.

Conclusions Among AAV, PAM is associated with the worse prognosis. Renal and cardiac failure, bacterial infections, and age at diagnosis >65y, are associated with a poor clinical outcome. Three of these factors are included in the revised version of FFS, supporting its usefulness as a prognostic score.

References

  1. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. ARD 2011;70:488–94.

  2. Guillevin L, C,Seror R,et al.The Five-Factor Score Revisited Assessment of Prognoses of Systemic Necrotizing Vasculitides. Medicine 2011;90:19-27.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.